Skip to main content
Theranexus logo

Theranexus — Investor Relations & Filings

Ticker · ALTHX ISIN · FR0013286259 LEI · 969500BFCV6IC7MFQP20 PA Manufacturing
Open in API
Filings indexed 286 across all filing types
Latest filing 2026-04-29 Annual Report
Country FR France
Listing PA ALTHX

About Theranexus

https://www.theranexus.com/en/

THX Pharma (formerly Theranexus) is an innovative, clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA). The company specializes in developing treatments for rare neurological disorders. It leverages a unique platform for the identification and characterization of advanced therapy drug candidates. Its lead program is a drug candidate in clinical development for Batten disease, a rare neurodegenerative disorder.

Recent filings

Filing Released Lang Actions
Attestation de la personne responsable
Annual Report Classification · 95% confidence The document is titled "DOCUMENT D'ENREGISTREMENT UNIVERSEL" and references the AMF (Autorité des Marchés Financiers), the French financial markets regulator. It mentions compliance with EU regulation 2017/1129, which relates to prospectuses for public offerings and admission of securities to trading. The document includes detailed sections such as risk factors, company history, financial situation, management, remuneration, and governance. It also references annual financial statements and audit reports incorporated by reference from previous years' filings. The length is substantial (15,000 characters), indicating it is a full report rather than a brief announcement. The content and structure align with a Universal Registration Document, which is a comprehensive annual report equivalent to an Annual Report (10-K) in the US context. It is not a mere announcement or certification, nor is it a transcript, call, or other specific filing type. Therefore, the best classification is Annual Report (10-K).
2026-04-29 French
THX Pharma Publishes Its 2025 Annual Results, Cash Position as of March 31, 2026, and Provides a Business Update
Earnings Release Classification · 85% confidence The document is a public press release announcing THX Pharma’s 2025 annual financial results, cash position, and business update. It presents key financial highlights, summary P&L figures, and narrative commentary, but is not the full statutory Annual Report (10-K) or Universal Registration Document itself. It matches the definition of an Earnings Release (initial announcement of periodical financial results). FY 2025
2026-04-28 English
THX Pharma publie ses résultats annuels 2025, sa trésorerie au 31 mars 2026 et fait le point sur ses activités
Earnings Release Classification · 85% confidence The text is a press release dated April 28, 2026 announcing THX Pharma’s annual results for the year ending December 31, 2025 (including a P&L summary table), the cash position as of March 31, 2026, and key operational highlights. It provides initial financial and operational highlights rather than the full statutory annual report, matching the definition of an Earnings Release. FY 2025
2026-04-28 French
THX Pharma annonce la publication de sa lettre aux actionnaires
Report Publication Announcement Classification · 90% confidence The document is a short press release (2,725 characters) announcing the publication of the company’s letter to shareholders and providing download and website links to access the full newsletter. It does not contain the actual letter content or detailed financials; it simply informs investors that the letter is now available. According to the “Menu vs Meal” rule, this is an announcement of a report being published, fitting the Report Publication Announcement (RPA) category.
2026-03-25 French
THX Pharma Announces the Publication of its Letter to Shareholders
Report Publication Announcement Classification · 95% confidence The document is a short press release (2,632 characters) announcing that THX Pharma’s letter to shareholders has been published and is available for download on the company website. It does not contain the actual report content or financial data, but simply directs shareholders to the published letter. This fits the definition of a Report Publication Announcement (RPA), which is used when a document states that a report is attached or available online without including the full report itself.
2026-03-25 English
THX Pharma annonce l'augmentation des moyens affectés au contrat de liquidité
Transaction in Own Shares Classification · 95% confidence The document is a formal announcement from THX Pharma regarding an increase in the cash allocation for its liquidity contract with Portzamparc – BNP Paribas. This type of disclosure, which details the adjustment of funds and shares held within a liquidity agreement, is a standard regulatory disclosure in the French market (AMF regulations). It does not involve a share buyback or issuance by the company itself, but rather the management of the liquidity provider's account. Therefore, it falls under the category of general regulatory announcements.
2026-02-25 French

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.